Assuntos
Adipocinas/sangue , Artrite Psoriásica/sangue , Autoantígenos/sangue , Biomarcadores/sangue , Lectinas/sangue , Índice de Gravidade de Doença , Adulto , Idoso , Anticorpos Monoclonais/uso terapêutico , Artrite Psoriásica/tratamento farmacológico , Proteína 1 Semelhante à Quitinase-3 , Feminino , Humanos , Infliximab , Masculino , Pessoa de Meia-Idade , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Adulto JovemRESUMO
Eccrine poroma frequently occurs as a solitary tumour, and only a few reports have described the occurrence of multiple lesions. Multiple eccrine poromas, or eccrine poromatosis, may occur in patients who have undergone radiotherapy and/or polychemotherapy. We report here four cases of multiple eccrine poromas in patients who were either undergoing, or had undergone, intensive chemotherapy (from 6 months to 16 years prior to onset). Three patients had non-Hodgkin's lymphoma and one had malignant fibrous histiocytosis. The number of lesions varied from 3 to > 20 in each patient, and all the lesions occurred on non-irradiated skin. The histopathological features were consistent with those of eccrine poroma, Pinkus type. In addition to radiation therapy, intensive chemotherapy may play a role in the pathogenesis of multiple eccrine poromas even many years after treatment.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Histiocitoma Fibroso Maligno/tratamento farmacológico , Linfoma não Hodgkin/tratamento farmacológico , Poroma/induzido quimicamente , Neoplasias das Glândulas Sudoríparas/induzido quimicamente , Idoso , Idoso de 80 Anos ou mais , Biópsia , Dermoscopia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Poroma/patologia , Neoplasias das Glândulas Sudoríparas/patologia , Fatores de TempoAssuntos
Adipocinas/sangue , Biomarcadores/sangue , Regulação da Expressão Gênica , Lectinas/sangue , Psoríase/metabolismo , Adolescente , Adulto , Idoso , Criança , Pré-Escolar , Proteína 1 Semelhante à Quitinase-3 , Ensaio de Imunoadsorção Enzimática/métodos , Feminino , Humanos , Inflamação , Masculino , Pessoa de Meia-Idade , Psoríase/diagnósticoRESUMO
BACKGROUND: Serum levels of S100A8/A9 may correlate with disease activity in psoriasis. OBJECTIVE: We sought to elucidate the association of serum levels of S100A8/A9 heterodimers with the clinical subtypes of psoriasis and the major cell source. METHODS: Serum samples were collected from patients with psoriasis vulgaris (n = 30), psoriatic arthritis (PA) (n = 16), pustular psoriasis (n = 24), and atopic dermatitis (n = 14) and from healthy control subjects (n = 21). Serum concentrations of S100A8/A9 were measured, and the expression levels were examined in psoriatic lesions. The messenger RNA levels were quantified in circulating monocytes and neutrophils. RESULTS: Serum levels of S100A8/A9 were significantly increased in all subtypes of psoriasis as compared with healthy controls and atopic dermatitis. Among the psoriatic subtypes, PA and pustular psoriasis showed remarkably high concentrations of S100A8/A9 heterodimers. The higher serum levels were associated with the presence of articular symptoms, but not significantly correlated with body surface areas of psoriatic lesions. S100A8 was expressed by both keratinocytes and infiltrating mononuclear cells, whereas S100A9 was predominantly expressed by neutrophils. The expression levels of S100A8 and S100A9 messenger RNA in monocytes were increased by approximately 2.25- and 1.91-fold in PA, respectively, whereas no significant increase was observed in psoriasis vulgaris and pustular psoriasis. LIMITATIONS: Difficulty in acquisition of clinical and laboratory samples in untreated patients, and of a sufficient number of subjects, were limitations. CONCLUSIONS: Although serum levels of S100A8/A9 were increased in all types of psoriasis examined, patients with PA had higher levels of S100A8/A9, probably because of an activated monocyte/macrophage system.